DysUFMylation of SREBP1 Promotes the Progression of Hepatocellular Carcinoma by Reprogramming Lipid Metabolism
UFMylation is a critical posttranslational modification that destabilizes SREBP1, and its dysregulation contributes to HCC progression. Targeting the UFMylation-SREBP1 axis, particularly through Fatostatin and Lenvatinib combination therapy, represents a novel therapeutic strategy for HCC.
Authors
- Ning Ren (ORCID: https://orcid.org/0000-0001-9776-2471)
- Zeping Han (ORCID: https://orcid.org/0000-0003-3804-7704)
- Min Xu (ORCID: https://orcid.org/0000-0001-9091-6757)
- Chenhao Zhou (ORCID: https://orcid.org/0000-0002-4800-3249)
- Zhu-Tao Wang
- Shuang–Jian Qiu (ORCID: https://orcid.org/0000-0003-2056-6127)
- Xiangyu Gao (ORCID: https://orcid.org/0000-0002-1697-1157)
- Yong Yi (ORCID: https://orcid.org/0000-0003-2792-6017)
- Dai Zhang (ORCID: https://orcid.org/0000-0002-9162-7401)
- Guoqiang Sun (ORCID: https://orcid.org/0000-0002-6317-1128)
- Hao Xiao (ORCID: https://orcid.org/0000-0002-9368-1495)
Institutions
- Fudan University (CN)
- Zhongshan Hospital (CN)
- Shanghai Tenth People's Hospital (CN)
Publication Details
- Journal
- Journal of Clinical and Translational Hepatology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.14218/jcth.2025.00318
- Citations
- 1
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94